Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$12.12M-81.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Henry O. Gosebruch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 452
- Beta
- 0.12
- Country
- BE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 13.56
Financials
Revenue
$12.12M-81.1%Net Income
$2.11MEBITDA
$-35.27MFree Cash Flow
$0.00EPS (diluted)
$0.03Shares Outstanding (diluted)
66.93M+2.1%Operating Expenses
$48.42MCash & Debt
$2.24BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.11B | $320.88M | $4.87 |
| 2024 | $275.65M | $74.08M | $1.12 |
| 2023 | $239.72M | $211.70M | $3.21 |
| 2022 | $241.25M | $-217.99M | $-3.32 |
| 2021 | $234.38M | $-103.23M | $-1.84 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $7.15
- Implied price
- $42.93
- Return from $29.37
- 7.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $21.34 — -27.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 2 | 4 | 6 | 8 | 10 |
|---|---|---|---|---|---|
| -2.0% | -21.4% | -9.7% | -2.1% | 3.7% | 8.4% |
| 3.0% | -17.4% | -5.1% | 2.9% | 9.0% | 14.0% |
| 8.0% | -13.4% | -0.5% | 7.9% | 14.3% | 19.5% |
| 13.0% | -9.4% | 4.1% | 12.9% | 19.6% | 25.0% |
| 18.0% | -5.4% | 8.7% | 17.9% | 24.9% | 30.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·6d ago·Neutral
…ber 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 21, 2026, and September 25, 2026, it has repurchased 106,060 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€…
View source ↗ - Newsmarketbeat.com·15d ago·Neutral
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig Lakefront Biotherapeutics American Depositary Shares NASDAQ: LKFT said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…ber 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 07, 2026 and September 11, 2026 it has repurchased 125,517 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) …
View source ↗ - Newsseekingalpha.com·21d ago·Neutral
…o Value Lakefront Biotherapeutics offers valuation support and clinical upside, leveraging a new development model post-Ouro acquisition and partnership with Gilead. LKFT's €2.24 billion liquidity and disciplined capital allocation provide runway through the first gamgertamig approval, with at least €1.6 billion projected post-approval. Gamgertamig's clinical promise targets difficult autoimmune diseases, but durable efficacy, safety, and competitive differentiation remain unproven and critical …
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
…ber 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 24/08/…
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
…ust 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 17/08…
View source ↗ - Newsglobenewswire.com·42d ago·Negative
… to Gamgertamig for the Treatment of Pemphigus Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (…
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Lakefront Receives Transparency Notification from Bank of America Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
…ust 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 10, 2026 and August 14, 2026, it has repurchased 107,871 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10/08…
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.83 per share
Typical surprise +104.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$0.03 vs $-0.82beat
- Wed, May 6$0.25 vs $-0.94beat
- Mon, Feb 23$13.90 vs $-0.13beat
- Wed, Nov 5$-3.54 vs $-0.48miss
- Wed, Jul 23$-1.85 vs $-0.23miss
- Wed, Apr 23$-2.67 vs $-0.14miss
Estimates and results for LKFT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in LKFT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.